Nanoparticle-mediated drug delivery for treating melanoma

Vaibhav Mundra, Wei Li, Ram I Mahato

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Melanoma originated from melanocytes is the most aggressive type of skin cancer with limited treatment options. New targeted therapeutic options with the discovery of BRAF and MEK inhibitors have shown significant survival benefits. Despite the recent progress, development of chemoresistance and systemic toxicity remains a challenge for treating metastatic melanoma. While the response from the first line of treatment against melanoma using dacarbazine remains only 5-10%, the prolonged use of targeted therapy against mutated oncogene BRAF develops chemoresistance. In this review, we will discuss the nanoparticle-based strategies for encapsulation and conjugation of drugs to the polymer for maximizing their tumor distribution through enhanced permeability and retention effect. We will also highlight photodynamic therapy and design of melanoma-targeted nanoparticles.

Original languageEnglish (US)
Pages (from-to)2613-2633
Number of pages21
JournalNanomedicine
Volume10
Issue number16
DOIs
StatePublished - Aug 1 2015

Fingerprint

Drug delivery
Nanoparticles
Melanoma
drug
Dacarbazine
Photodynamic therapy
encapsulation
permeability
Mitogen-Activated Protein Kinase Kinases
Encapsulation
tumor
Pharmaceutical Preparations
Toxicity
Tumors
inhibitor
cancer
skin
Skin
Polymers
polymer

Keywords

  • active targeting
  • metastatic melanoma
  • multidrug resistance
  • nanoparticles
  • photodynamic therapy
  • polymer-drug conjugate
  • tumor initiating cells

ASJC Scopus subject areas

  • Materials Science(all)
  • Bioengineering
  • Biomedical Engineering
  • Medicine (miscellaneous)
  • Development

Cite this

Nanoparticle-mediated drug delivery for treating melanoma. / Mundra, Vaibhav; Li, Wei; Mahato, Ram I.

In: Nanomedicine, Vol. 10, No. 16, 01.08.2015, p. 2613-2633.

Research output: Contribution to journalArticle

Mundra, Vaibhav ; Li, Wei ; Mahato, Ram I. / Nanoparticle-mediated drug delivery for treating melanoma. In: Nanomedicine. 2015 ; Vol. 10, No. 16. pp. 2613-2633.
@article{6ae8c1208f364f7890fc360aa3103ced,
title = "Nanoparticle-mediated drug delivery for treating melanoma",
abstract = "Melanoma originated from melanocytes is the most aggressive type of skin cancer with limited treatment options. New targeted therapeutic options with the discovery of BRAF and MEK inhibitors have shown significant survival benefits. Despite the recent progress, development of chemoresistance and systemic toxicity remains a challenge for treating metastatic melanoma. While the response from the first line of treatment against melanoma using dacarbazine remains only 5-10{\%}, the prolonged use of targeted therapy against mutated oncogene BRAF develops chemoresistance. In this review, we will discuss the nanoparticle-based strategies for encapsulation and conjugation of drugs to the polymer for maximizing their tumor distribution through enhanced permeability and retention effect. We will also highlight photodynamic therapy and design of melanoma-targeted nanoparticles.",
keywords = "active targeting, metastatic melanoma, multidrug resistance, nanoparticles, photodynamic therapy, polymer-drug conjugate, tumor initiating cells",
author = "Vaibhav Mundra and Wei Li and Mahato, {Ram I}",
year = "2015",
month = "8",
day = "1",
doi = "10.2217/nnm.15.111",
language = "English (US)",
volume = "10",
pages = "2613--2633",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "16",

}

TY - JOUR

T1 - Nanoparticle-mediated drug delivery for treating melanoma

AU - Mundra, Vaibhav

AU - Li, Wei

AU - Mahato, Ram I

PY - 2015/8/1

Y1 - 2015/8/1

N2 - Melanoma originated from melanocytes is the most aggressive type of skin cancer with limited treatment options. New targeted therapeutic options with the discovery of BRAF and MEK inhibitors have shown significant survival benefits. Despite the recent progress, development of chemoresistance and systemic toxicity remains a challenge for treating metastatic melanoma. While the response from the first line of treatment against melanoma using dacarbazine remains only 5-10%, the prolonged use of targeted therapy against mutated oncogene BRAF develops chemoresistance. In this review, we will discuss the nanoparticle-based strategies for encapsulation and conjugation of drugs to the polymer for maximizing their tumor distribution through enhanced permeability and retention effect. We will also highlight photodynamic therapy and design of melanoma-targeted nanoparticles.

AB - Melanoma originated from melanocytes is the most aggressive type of skin cancer with limited treatment options. New targeted therapeutic options with the discovery of BRAF and MEK inhibitors have shown significant survival benefits. Despite the recent progress, development of chemoresistance and systemic toxicity remains a challenge for treating metastatic melanoma. While the response from the first line of treatment against melanoma using dacarbazine remains only 5-10%, the prolonged use of targeted therapy against mutated oncogene BRAF develops chemoresistance. In this review, we will discuss the nanoparticle-based strategies for encapsulation and conjugation of drugs to the polymer for maximizing their tumor distribution through enhanced permeability and retention effect. We will also highlight photodynamic therapy and design of melanoma-targeted nanoparticles.

KW - active targeting

KW - metastatic melanoma

KW - multidrug resistance

KW - nanoparticles

KW - photodynamic therapy

KW - polymer-drug conjugate

KW - tumor initiating cells

UR - http://www.scopus.com/inward/record.url?scp=84940497441&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940497441&partnerID=8YFLogxK

U2 - 10.2217/nnm.15.111

DO - 10.2217/nnm.15.111

M3 - Article

VL - 10

SP - 2613

EP - 2633

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 16

ER -